Canadian Journal of Diabetes · 2019 · 17 citations · 13 references
MedicineEndocrinologyInternal MedicineClinical PharmacologyDiabetologyGeneral Internal MedicineDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyGlycemic ControlInsulin TherapyBasal Insulin TherapyCohort Study InvestigationDiabetes Mellitus EvaluationGlycemic Control TargetsGlycemic TargetsHealth Outcomes AnalysisInsulin ManagementRetrospective Case Study
OBJECTIVES: This study evaluated real-world clinical outcomes of patients with type 1 diabetes (T1D) and type 2 diabetes (T2D) initiating or transferring to insulin glargine 300 U/mL (Gla-300) vs insulin glargine 100 U/mL (Gla-100). METHODS: This is a retrospective cohort study using data from the Canadian LMC Diabetes Patient Registry. The 4 following cohorts were analyzed: 1) insulin-naïve patients with T2D who initiated Gla-300 or Gla-100, 2) patients with T2D who switched from neutral protamine Hagedorn (NPH) or detemir to Gla-300 or Gla-100, 3) patients with T2D who switched from Gla-100 to Gla-300 and 4) patients with T1D who switched from Gla-100, NPH or detemir to Gla-300. RESULTS: Of 376 propensity score-matched insulin-naïve patients, 6-month reduction in glycated hemoglobin (A1C) was similar between Gla-300 (-1.78%±1.85%; p<0.001) and Gla-100 (-1.74%±1.87%; p<0.001). In 114 propensity score-matched patients who switched from NPH or detemir, 6-month reduction in A1C was similar between Gla-300 (-0.78%±1.14%) and Gla-100 (-0.70%±1.57%). The 396 patients who switched from Gla-100 to Gla-300 had a significant reduction in A1C (-0.45%±1.39%; p<0.001). In 196 patients with T1D who switched from Gla-100, NPH or detemir to Gla-300, there was a significant reduction in A1C of -0.17%±1.19% (p=0.04). CONCLUSIONS: In a real-world clinical setting, insulin-naïve patients who initiated Gla-300 or Gla-100 showed similar changes in A1C and weight. Patients with T1D or T2D using Gla-300 transferred from another basal insulin had significant reductions in A1C with no change in weight or insulin dose.
13
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetes Care · 2014 · 3.1K citations · Full text
Matthew C. Riddle, Julio Rosenstock, John Gerich · Diabetes Care · 2003 · 1.5K citations · Full text
Silvio E. Inzucchi, Richard M. Bergenstal, John B. Buse et al. · Diabetologia · 2015 · 690 citations · Full text
Matthew C. Riddle, Geremia B. Bolli, M. Ziemen et al. · Diabetes Care · 2014 · 360 citations